Duke Cancer Institute researchers have observed how stem cell mutations quietly arise and spread throughout a widening field of the colon until they eventually predominate and become a malignancy.
Homologous recombination deficiency tests are used routinely in the clinic to determine which patients get PARP inhibitors.
